116 related articles for article (PubMed ID: 35172148)
1. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.
Ramesh P; Di Franco S; Atencia Taboada L; Zhang L; Nicotra A; Stassi G; Medema JP
Cell Rep; 2022 Feb; 38(7):110374. PubMed ID: 35172148
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
[TBL] [Abstract][Full Text] [Related]
3. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
4. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S
Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
Guo T; Gu C; Li B; Xu C
Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
7. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
[TBL] [Abstract][Full Text] [Related]
8. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
9. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
[TBL] [Abstract][Full Text] [Related]
10. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
11. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
12. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
Wang Q; Wan J; Zhang W; Hao S
Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.
Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT
Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786
[TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract][Full Text] [Related]
15. Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
Bonnefond ML; Lambert B; Giffard F; Abeilard E; Brotin E; Louis MH; Gueye MS; Gauduchon P; Poulain L; N'Diaye M
Apoptosis; 2015 Apr; 20(4):535-50. PubMed ID: 25627260
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
17. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.
Zeuner A; Francescangeli F; Contavalli P; Zapparelli G; Apuzzo T; Eramo A; Baiocchi M; De Angelis ML; Biffoni M; Sette G; Todaro M; Stassi G; De Maria R
Cell Death Differ; 2014 Dec; 21(12):1877-88. PubMed ID: 25034785
[TBL] [Abstract][Full Text] [Related]
18. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
19. BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells.
Afreen S; Bohler S; Müller A; Demmerath EM; Weiss JM; Jutzi JS; Schachtrup K; Kunze M; Erlacher M
Cell Death Dis; 2020 Jan; 11(1):8. PubMed ID: 31907357
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
